{
    "clinical_study": {
        "@rank": "161336", 
        "arm_group": [
            {
                "arm_group_label": "DWJ1276", 
                "arm_group_type": "Experimental", 
                "description": "Once daily, administered orally, 8 week"
            }, 
            {
                "arm_group_label": "Olmesartan", 
                "arm_group_type": "Active Comparator", 
                "description": "Once daily, administered orally, 8 week"
            }, 
            {
                "arm_group_label": "Rosuvastatin", 
                "arm_group_type": "Active Comparator", 
                "description": "Once daily, administered orally, 8 week"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Once daily, administered orally, 8 week"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of DWJ1276"
        }, 
        "brief_title": "Clinical Study for Patients With Hypertension Associated With Dyslipidemia", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Hypertension", 
            "Dyslipidemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Dyslipidemias"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult male and female in between ages of 20 and 80 at the time of screening\n\n          -  Subject who can understand information provided and who can sign written consent\n             voluntarily\n\n        Exclusion Criteria:\n\n          -  Patients with hypersensitivity to olmesartan and rosuvastatin\n\n          -  Pregnant or lactating women and fertile women who is not using proper contraceptive\n             method\n\n          -  Patient with history of drug or alcohol abuse"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01764295", 
            "org_study_id": "DW_DWJ1276003"
        }, 
        "intervention": [
            {
                "arm_group_label": "DWJ1276", 
                "intervention_name": "DWJ1276", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Olmesartan", 
                "intervention_name": "Olmesartan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Rosuvastatin", 
                "intervention_name": "Rosuvastatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Olmesartan", 
                "Olmesartan medoxomil", 
                "Rosuvastatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Seoul National University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "Multi-institutional, Randomized, Double-Blind, Placebo-Control, Factorial Design, 4-arms, 8 Week Administration, Phase 3 Clinical Study for Patients With Hypertension Associated With Dyslipidemia", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "LDL-C percent change of DWJ1276 from baseline", 
                "safety_issue": "No", 
                "time_frame": "8weeks"
            }, 
            {
                "measure": "DBP change of DWJ1276 from baseline", 
                "safety_issue": "No", 
                "time_frame": "8weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01764295"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of subjects who reached LDL-C treatment goal defined by NCEP ATP III guideline", 
                "safety_issue": "No", 
                "time_frame": "8weeks"
            }, 
            {
                "measure": "Proportion of subjects who reached blood pressure treatment goal defined by JNC VII report", 
                "safety_issue": "No", 
                "time_frame": "8weeks"
            }
        ], 
        "source": "Daewoong Pharmaceutical Co. LTD.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Daewoong Pharmaceutical Co. LTD.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}